Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 24, 2017
Pharmacy Choice - Pharmaceutical News - American-made biosimilars a differentiator in US market, Coherus [Sudan Tribune] - October 24, 2017

Pharmacy News Article

 3/17/17 - American-made biosimilars a differentiator in US market, Coherus [Sudan Tribune]

US patients and physicians favour domestically-made biosimilars according to Coherus Biosciences. But if quality is assured should the manufacturing location matter?

The first biosimilar product was launched in the US in 2015. And while there are currently four approved, this number is expected to skyrocket over the next few years.

Take AbbVies Humira (adalimumab), for example: over 30 companies are developing a biosimilar version of it, chasing a market worth over $16bn annually, $10.4bn of which comes from the US.

Therefore companies have looked to a number of variables to differentiate their product in a potentially crowded marketplace. These range from the speed to market and heavy price discounts , to physician/patient educational efforts and potentially even brand name marketing .

But in a results earning call this week, Coherus Biosciences CEO Denny Lanfear said his company has conducted research showing providers and patients prefer a biosimilar manufacturer in the US.

Biopharma-Reporter contacted the firm, and while spokesman Patrick O`Brien would not share this research, he said the firm believes having an American-made product will make a difference in the US marketplace.

But we also contacted Novartis subsidiary Sandoz, makers of the first US biosimilar Zarxio (filgrastim) and the largest biosimilar developer by revenue. The firm has three dedicated production sites for its global biosimilar products, two in Austria, one in Slovenia, but none in the US.

And while spokesman Chris Lewis would not comment on other peoples perceptions about potential stakeholder preferences, he told us:

We sincerely hope any decisions related to manufacturing sites will be made based on the quality, excellence and scientific expertise demonstrated by those sites, not on factors such as location.

An official from another biosimilar developer told us: "The location of manufacturing may matter from a political perspective [President Trump has pledged to bring drug production back to the US ], but when it comes to earning stakeholder trust around product quality, the things that matter most to physicians are clinical and post-market data which show how well a drug works for patients.

"Ultimately, individual biosimilar products will win on quality and affordability, not on nationalistic whims."

And now we look to you, our loyal Biopharma-Reporter readers, for your views on this issue. Feel free to leave a comment and to answer the following questions:

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Last Chance
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Oct 30: Medication Safety & Drug Safety Alerts
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement